 |
|
АкушерствоАнатомияАнестезиологияВакцинопрофилактикаВалеологияВетеринарияГигиенаЗаболеванияИммунологияКардиологияНеврологияНефрологияОнкологияОториноларингологияОфтальмологияПаразитологияПедиатрияПервая помощьПсихиатрияПульмонологияРеанимацияРевматологияСтоматологияТерапияТоксикологияТравматологияУрологияФармакологияФармацевтикаФизиотерапияФтизиатрияХирургияЭндокринологияЭпидемиология |
ТЕРАПИЯ ОИПЭффективной терапии ОИП в настоящее время не существует. В большинстве описанных случаев ОИП больные получали высокие дозы глюкокортикостероидов, однако, несмотря на это, летальность при этом заболевании очень высока. Относительно недавно была показана эффективность метилпреднизолона у больных с фибропролиферативной фазой ОРДС (позже 5 - 10го дня от начала заболевания): отмечено улучшение индекса повреждения легких, полиорганной недостаточности и улучшение выживаемости больных в течение 60 дней. Однако, несмотря на сходную морфологическую картину при ОИП и ОРДС, данные заболевания имеют различный патогенез, что, вероятно, может объяснить различную эффективность терапии стероидами - очень часто при ОИП они не приводят к улучшению клинической картины. Тем не менее эксперты рекомендуют использование при ОИП метилпреднизолона в/в в дозе 2 мг/(кгxсут). В ранних работах при быстро прогрессирующем легочном фиброзе была отмечена эффективность внутривенной комбинированной терапии преднизолоном (250 мг/сут), циклофосфамидом (1,5 г/сут) и винкристином (2 мг/сут). Robinson и соавт. описали случай эффективной терапии больного с ОИП комбинацией циклоспорина, азатиоприна и преднизолона. Недавно Suratt и соавт. представили положительный опыт использования интерферона-гамма (50 - 100 мкг 3 раза в неделю) у пациента с ОИП, индуцированной кармустином и лучевой терапией. Обязательными компонентами терапии ОИП являются кислородотерапия и респираторная поддержка. Тактика респираторной поддержки не отличается от той, что принята в настоящее время при ОРДС - протективная вентиляция легких. Возможно, улучшить прогноз при ОИП помогут новые препараты - экзогенный сурфактант, антицитокиновые антитела, оксид азота. СПИСОК ЛИТЕРАТУРЫ 1.Akira M, Hamada H, Sakatani M, et al. CT findings during accelerated deterioration in patients with idiopathic pulmonary fibrosis. Am J Roentgenol 1997; 168: 79-83. 2.Ambrosini V, Cancellieri A, Chilosi M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J 2003; 22: 821 - 826. 3.American Thoracic Society. Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment. International Consensus Statement. Am J Respir Crit Care Med 2000; 161: 646-664 4.American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304. 5.Askin FB. Back to the future: The Hamman-Rich syndrome and acute interstitial pneumonia. Mayo Clin Proc 1990; 65: 1624-26. 6.Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997; 156: 1897-1901. 7.Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199 - 203. 8.Bonaccorsi A, Cancellieri A, Chilosi M, Trisolini R, Boaron M, Crimi N, Poletti V. Acute interstitial pneumonia: report of a series. Eur Respir J 2003; 21: 187- 191. 9.Bouros D, Nicholson AC, Polychronopoulos V, du Bois RM. Acute interstitial pneumonia. Eur Respir J 2000; 15: 412-418. 10.British Thoracic Society recommendations. The diagnosis, assessment and treatment of diffuse parenchymal disease in adults. Thorax 1999; 54 (Suppl.1): S1- S30. 11.Carrington CB, Gaensler EA, Coutu RE, et al. Usual and desquamative interstitial pneumonia. Chest 1976; 69: 261-263. 12.Cha SI, Fesler MB, Cool CD, et al. Lymphoid interstitial pneumonia: clinical features, associations and prognosis. Eur Respir J 2006; 28: 364-69. 13.Cordier J-F. Cryptogenic organising pneumonia. Eur Respir J 2006; 28: 422 - 446. 14.Corrin B. Pathology of interstitial lung diseases. Semin Resp Crit Care Med 1994; 15: 61-76. 15.Cottin V, Donsbeck AV, Revel D, et al. Nonspecific interstitial pneumonia. Individualization of a clinicopathologic entity in a series of 12 patients. Am J Respir Crit Care Med 1998; 158: 1286-1293. 16.Daniil ZD, Gilchrist FC, Nicholson AG, et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999; 160: 899 - 905. 17.Davison AG, Heard BE, McAllister WAC, Turner-Warwick MEH. Cryptogenic organizing pneumonitis. Q J Med 1983; 52: 382-394. 18.Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis: a randomized prospective study. Am J Respir Crit Care Med 1998; 158: 220-225 19.Epler GR, Colby TV, McLoud TC, et al. Bronchiolitis obliterans organizing pneumonia. N Engl J Med 1985; 312: 152-158. 20.Flaherty KR, Martinez FJ. Nonspecific interstitial pneumonia. Semin Respir Crit Care Med 2006; 27: 652 - 658. 21.Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001; 164: 1722-1727. 22.Hamman L, Rich AR. Fulminating diffuse interstitial fibrosis of the lungs. Trans Am Clin Climat Assoc 1935; 51: 154-63. 23.Hartman TE, Primack SL, Swensen SJ, Hansell D, McGuinness G, Müller NL. Desquamative interstitial pneumonia: thin-section CT findings in 22 patients. Radiology 1993; 187: 787 - 790. 24.Heynemann LE, Ward S, Lynch DA, et al. Respiratory bronchiolitis, respiratory bronchiolitis-associated interstitial lung disease, and desquamative interstitial pneumonia: different entities or part of the spectrum of the same disease process? AJR Am J Roentgenol 1999; 173: 1617 - 1622. 25.Ichikado K, Johkoh T, Ikezoe J, et al. Acute interstitial pneumonia: high-resolution CT findings correlated with pathology. Am J Roentgenol 1997; 168:333-338. 26.Ichikawa Y, Kinoshita M, Koga T, et al. Lung cyst formation in lymphocytic interstitial pneumonia: CT features. J Comput Assist Tomogr 1994; 18: 745-748. 27.Johkoh T, Muller NL, Taniguchi H, et al. Acute interstitial pneumonia: Thin-section CT findings in 36 patients. Radiology 1999; 211: 859-63. 28.Johkoh T, Ichikado K, Akira M, et al. Lymphocytic interstitial pneumonia: Follow-up CT findings in 14 patients. J Thorac Imaging 2000; 15: 162-167. 29.Johnson MA, Kwan S, Snell NJC, et al. Randomized controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280-288. 30.Johnston IDA, Prescott RJ, Chalmers JC, et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax 1997; 52: 38-44. 31.Katzenstein AL, Fiorelli RF. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994; 18: 136-147. 32.Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157: 1301-1315. 33.Katzenstein AL, Myers JL, Mazur MT. Acute interstitial pneumonia: a clinicopathologic, ultrastructural, and cell kinetic study. Am J Surg Pathol 1986; 10: 256-267. 34.Katzenstein AL, Zisman DA, Litzky LA, et al. Usual interstitial pneumonia: histologic study of biopsy and explant specimens. Am J Surg Pathol 2002; 26: 1567-1577. 35.Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby Т. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006; 27:143-150. 36.King Jr TE, Tooze JA, Schwarz MI, Brown KR, Cheriack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171- 81. 37.Kondoh Y, Taniguchi H, Kawabata Y, et al. Acute exacerbation in idiopathic pulmonary fibrosis: analysis of clinical and pathological findings in three cases. Chest 1993; 103: 1808 - 1812. 38.Lama VN, Flaherty KR, TowesGB, Colby TV, Travis WD, Long Q, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 1084-90. 39.Lazor R, Vandevenne A, Pelletier A, et al. Cryptogenic organizing pneumonia: characteristics of relapses in a series of 48 patients. Am J Respir Crit Care Med 2000; 162: 571 - 577. 40.Liebow AA, Steer A, Billingsley JG. Desquamative interstitial pneumonia. Am J Med 1965; 39: 369 - 404. 41.Liebow AA, Carrington CB. Diffuse pulmonary lymphoreticular infiltrations associated with dysproteinemia. Med Clin North Am 1973; 57: 809-843. 42.Nagai S, Kitaichi M, Itoh H, et al. Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. Eur Respir J 1998; 12: 1010-1019. 43.Nagai S, Kitaichi M, Izumi T. Classification and recent advances in idiopathic interstitial pneumonia. Curr Opin Pulm Med 1998; 4: 256-260. 44.Nicholson AG. Classification of idiopathic interstitial pneumonias: making sense of the alphabet soup. Histopathology 2002; 41: 381-391. 45.Nicholson AG, Colby TV, Wells AU. Histopathological approach to patterns of interstitial pneumonia in patient with connective tissue disorders. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 10-17. 46.Olson J, Colby TV, Elliott CG. Hamman-Rich syndrome revisited. Mayo Clin Proc 1990; 65:1538-1548. 47.Quefatieh A, Stone CH, Digiovine B, Toews GB, Hyzy RC. Low hospital mortality in patients with acute interstitial pneumonia. Chest 2003; 124: 554-559. 48.Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective, double-blind randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144: 291-296. 49.Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999; 159: 1061-1069. 50. Raghu G, Mageto YN, Lockhart D, et al. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease. A prospective study. Chest 1998; 116: 1168- 1174. 51.Ryu JH, Myers JL, Capizzi SA, et al. Desquamative interstitial pneumonia and respiratory bronchiolitis-associated interstitial lung disease. Chest 2005; 127: 178 - 184. 52.Schwartz DA, Van Fossen DS, Davis CS, et al. Determinants of progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149: 444-449 53.Selman M, Carrillo G, Salas J, et al.Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest 1998; 114: 507-512. 54.Selman M, King Jr TE, Pardo A: Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implication for therapy. Ann Intern Med 2001; 134:136-151. 55.Vourlekis JS, Brown KK, Cool CD, Young DA, Cherniack RM, King TE Jr,, Schwarz MI. Acute interstitial pneumonitis. Case series and review of the literature. Medicine (Baltimore) 2000; 79: 369-378. 56.Watanabe K, Higuchi K, Ninomiya K, et al. Steroid treatment based on the findings of transbronchial biopsy in idiopathic interstitial pneumonia. Eur Respir J 2002; 20: 1213-1219. 57.Yousem SA, Colby TV, Gaensler EA. Respiratory bronchiolitis-associated interstitial lung disease and its relationship to desquamative interstitial pneumonia. Mayo Clin Proc 1989; 64: 1373 - 1380 58.Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341: 1264-1269.
document: $pr: version: 01-2007.1 codepage: windows-1251 type: klinrek id: kli57158322 : 11.2. ПОРАЖЕНИЯ ОРГАНОВ ДЫХАНИЯ ПРИ СИСТЕМНЫХ ЗАБОЛЕВАНИЯХ СОЕДИНИТЕЛЬНОЙ ТКАНИ meta: author: fio[ru]: Л.П. Ананьева, А.В. Волков, А.В. Смирнов, О.А. Антелава codes: next: type: dklinrek code: III.VI type: dkli00023 Дата добавления: 2015-01-18 | Просмотры: 1000 | Нарушение авторских прав |